June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy. FDA approved the BTK inhibitor to treat MCL in November (see “BeiGene Enters U.S. Market with

Read the full 621 word article

How to gain access

Continue reading with a
two-week free trial.